---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-023427"
form_type: "8-K"
ticker: "CMPS"
cik: "0001816590"
company_name: "COMPASS Pathways plc"
filed_at: "2025-05-08T23:59:59+00:00"
generated_at: "2026-05-22T05:17:16.623427+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Compass Pathways Q1 net loss $17.9M; cash $260.1M; phase 3 top-line data expected late June

## Summary
- Net loss $17.9M ($0.24 diluted EPS) vs $35.2M ($0.55) in Q1 2024; includes $19.5M non-cash gain on warrant liabilities.
- R&D expenses $30.9M, up 24% YoY due to advancing COMP360 phase 3 trials; G&A $18.7M, up 36%.
- Cash $260.1M at Mar 31, 2025, vs $165.1M at Dec 31, 2024; net cash raised $140.4M in Q1.
- Top-line 6-week data from COMP005 phase 3 in TRD expected late June 2025; COMP006 26-week data H2 2026.
- Full-year 2025 net cash used in ops guided at $120M-$145M; cash expected to fund through COMP006 readout.

## SEC filing metadata
- accession: 0001628280-25-023427
- form_type: 8-K
- ticker: CMPS
- cik: 0001816590
- company_name: COMPASS Pathways plc
- filed_at: 2025-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1816590/000162828025023427/0001628280-25-023427-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1816590/000162828025023427/cmps-20250508.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-023427
- JSON: https://secwatch.observer/filing/0001628280-25-023427.json
- Plain text: https://secwatch.observer/filing/0001628280-25-023427.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.